AAAAAA

   
Results: 1-4 |
Results: 4
CURDLAN SULFATE (CRDS) IN A 21-DAY INTRAVENOUS TOLERANCE STUDY IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) AND CYTOMEGALOVIRUS (CMV) INFECTED PATIENTS - ANTI-CMV ACTIVITY WITH LOW TOXICITY
Authors: GORDON M DEEKS S DEMARZO C GOODGAME J GURALNIK M LANG W MIMURA T PEARCE D KANEKO Y
Citation: M. Gordon et al., CURDLAN SULFATE (CRDS) IN A 21-DAY INTRAVENOUS TOLERANCE STUDY IN HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) AND CYTOMEGALOVIRUS (CMV) INFECTED PATIENTS - ANTI-CMV ACTIVITY WITH LOW TOXICITY, Journal of medicine, 28(1-2), 1997, pp. 108-128
A PHASE-II CONTROLLED-STUDY OF A COMBINATION OF THE IMMUNE MODULATOR,LENTINAN, WITH DIDANOSINE (DDI) IN HIV PATIENTS WITH CD4 CELLS OF 200-500 MM(3)/
Authors: GORDON M GURALNIK M KANEKO Y MIMURA T GOODGAME J DEMARZO C PIERCE D BAKER M LANG W
Citation: M. Gordon et al., A PHASE-II CONTROLLED-STUDY OF A COMBINATION OF THE IMMUNE MODULATOR,LENTINAN, WITH DIDANOSINE (DDI) IN HIV PATIENTS WITH CD4 CELLS OF 200-500 MM(3)/, Journal of medicine, 26(5-6), 1995, pp. 193-207
FURTHER CLINICAL-STUDIES OF CURDLAN SULFATE (CRDS) - AN ANTI-HIV AGENT
Authors: GORDON M GURALNIK M KANEKO Y MIMURA T GOODGAME J LANG W
Citation: M. Gordon et al., FURTHER CLINICAL-STUDIES OF CURDLAN SULFATE (CRDS) - AN ANTI-HIV AGENT, Journal of medicine, 26(3-4), 1995, pp. 97-131
A PHASE-I STUDY OF CURDLAN SULFATE - AN HIV INHIBITOR - TOLERANCE, PHARMACOKINETICS AND EFFECTS ON COAGULATION AND ON CD4 LYMPHOCYTES
Authors: GORDON M GURALNIK M KANEKO Y MIMURA T BAKER M LANG W
Citation: M. Gordon et al., A PHASE-I STUDY OF CURDLAN SULFATE - AN HIV INHIBITOR - TOLERANCE, PHARMACOKINETICS AND EFFECTS ON COAGULATION AND ON CD4 LYMPHOCYTES, Journal of medicine, 25(3-4), 1994, pp. 163-180
Risultati: 1-4 |